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Uma série de organosselenanas foi sintetizada utilizando-se uma metodologia quimio-
enzimática. Estas organosselenanas apresentam variações na estereoquímica e no halogênio 
ligado ao átomo de selênio. Devido à reação característica envolvendo compostos de selênio e 
tióis, estas organosselenanas foram avaliadas como inibidores de cisteíno proteases (catepsinas 
V e S). As constantes de inibição de segunda-ordem mostraram que a catepsina S é inibida mais 
rapidamente do que a catepsina V. Pode-se observar que as organosselenanas dibromadas são 
inibidores mais potentes do que as dicloradas. Desta forma, os resultados obtidos mostram que 
compostos hipervalentes de selênio podem ser aplicados como inibidores de cisteíno proteases.
A series of organoselenium dihalides (organoselenanes) was synthesized from organoselenides 
using a chemoenzymatic approach. The organoselenanes have variations in their stereochemistry 
and in the halogen atom bonded to the selenium atom. Because of the unique selenium-thiol 
chemistry displayed by several organoselenium compounds, the organoselenanes were evaluated 
as new potential inhibitors of cysteine proteases (cathepsins S and V). By the analysis of the 
second-order rate constants of the inhibition of cathepsin S and V, it was possible to conclude 
that organoselenanes inhibited the cathepsin S faster than cathepsin V. It was observed higher 
inhibitory potencies for the dibromo organoselenanes derivatives than the dichloro analogues. In 
addition, the present data suggest the use of hypervalent selenium compounds as novel motifs for 
cysteine proteases inhibitors.
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Introduction
The selenium compounds biological properties have 
been widely investigated,1 especially because selenium is 
an essential trace element for mammals and organisms.2 
Selenium was found to compose glutathione peroxidase 
enzymes (GPx), which are pivotal protective enzymes of cells 
against oxidizing agents.3 The antioxidant activity has been 
the main studied biological property for organoselenium(II) 
compounds (organoselenides)4 due to the possibility of these 
selenium-containing compounds act as mimetics of GPx. 
Because of their antioxidant properties, organoselenides 
have been studied as antitumor, anti-inflammatory and anti-
infective agents,5 furthermore, it has been widely reported 
that selenium acts as chemopreventive agents6 and is used 
as a micronutrient-containing foods.7 It was observed that 
selenium compounds increase the antitumor activity of 
anticancer drugs and protect against drug-induced toxicity,8 
induce apoptosis mainly because of their interaction with 
thiol-dependent enzymes.9 This remarkable ability of 
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selenium derivatives to inhibit some enzymes relies on 
their unique selenium-thiol chemistry.10 In the case of 
hypervalent selenium(IV) compounds, the affinity by thiol 
groups is well known as the reduction of diorganoselenium 
dichloro to selenides mediated by thiourea,11 the reaction 
of selenoxides with thiols leading to selenides12 and the 
organoselenone moiety displacement by thiols. Biologically, 
it was demonstrated that organoseleninic acids also inhibit 
thiol-dependent protein tyrosine phosphatases,13 due to the 
particular reactivity of selenium(IV) atom in seleninic acids 
with thiols,14 but there is still a lack on the application of these 
particular reactivities of hypervalent selenium compounds 
in biological systems.
Inspired by the sulfur reactivity with selenium 
compounds, we looked at the cysteine cathepsins, which 
are lysosomal cysteine proteases, and are often upregulated 
in various human cancers. They have been implicated 
in distinct tumorigenic processes, such as angiogenesis, 
proliferation, and apoptosis and invasion.15 The human 
family of cysteine cathepsins has 11 members (cysteine 
cathepsin B, C, F, H, K, L, O, S, V, W and X), which 
share a conserved active site that is formed by cysteine, 
histidine and asparagine residues.16 Based on the structural 
catalytic proprieties of cysteine proteases and selenium(IV) 
chemistry, we report our investigation on the creation 
of a new class of selenium-containing compounds, 
organoselenanes (selenium(IV) compounds), to be used 
as novel inhibitors of human cysteine cathepsins S and V. 
Results and Discussion
In this work, we prepared a small series of selenium-
containing compounds to be investigated as possible 
inhibitors of cysteine cathepsins, through which was 
possible to evaluate the influence of structural elements, 
such as the chirality and the effect of halogen derivatives 
(Figure 1).
Synthesis of the achiral organoselenanes 1-2 
The achiral organoselenanes 1-2 were synthesized 
from the bromo-benzylic alcohol 7. Initially, this alcohol 
was transformed into methyl ether 8, which was converted 
into selenide 9 by a bromine/lithium exchange reaction 
followed by the capture of the organolithium intermediate 
with dibutyl diselenide leading to the selenide 9 in 70% 
yield. When the selenide 9 was reacted with SO2Cl2 the 
dichloro organoselenane 1 was obtained (> 99% yield). In 
the same way, the dibromo organoselenane 2 was prepared 
from 9 by Se-oxidative reaction with Br2 in high yield 
(> 99%; Scheme 1).
Synthesis of the chiral organoselenanes 3-4 and 5-6
In order to synthesize the chiral organoselenanes 3-4 
and 5-6 a chemoenzymatic methodology was developed. 
Initially, the ketone 11 was synthesized in 45% yield from 
2’-amino-acetophenone 10 by using arenediazonium salt 
and lithium butylselenolate (Scheme 2). Then, reduction of 
the ketone 11 afforded the desired chiral seleno-alcohol 12.
Enzymatic kinetic resolution of the alcohol (RS)-12 
through lipase-catalyzed acetylation was employed 
to obtain each enantiomer separately. The enzymatic 
resolution of racemic alcohol 12 was carried out with 
vinyl acetate as an acyl donor and CAL-B as biocatalyst 
(Scheme 3). This reaction was performed in hexane during 
24 h, and the alcohol (S)-12 and ester (R)-13 were obtained 
in high enantiomeric excess (up to 99%).
After enzymatic kinetic resolution, the compounds 
(S)-12 and (R)-13 were purified by flash chromatography 
and both compounds were obtained in high isolated yield 
Figure 1. New organoselenanes for inhibition of human cysteine 
cathepsins.
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Scheme 1. Reagents and conditions. (i) a: NaH, THF (0 oC, 30 min); b: MeI, (rt, 2 h); (ii) a: t-BuLi, THF (−78-0 oC, 30 min); b: BuSeSeBu, THF (rt, 3 h); 
(iii) SO2Cl2 or Br2, THF (0 oC, 15 min).
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(45%). The alcohol (R)-12 was obtained by hydrolysis 
of the ester (R)-13. Thus, by using enzymatic kinetic 
resolution it was possible to obtain separately both alcohol 
enantiomers 12 in excellent enantiomeric excess (> 99%).
The next step, the enantiomerically pure seleno-alcohols 
(S)-12 and (R)-12 were transformed into their respective 
ethers (S)-14 and (R)-14 in high yields (86% and 89%, 
respectively). The organoselenides (S)-14 and (R)-14 were 
reacted with SO2Cl2 and the dichloro organoselenanes 3 
and 4 were obtained in high yields (> 99%). In the same 
way, the dibromo organoselenanes 5 and 6 were prepared 
from (S)-14 and (R)-14 by Se-oxidative reaction with Br2 
in high yield (> 99%; Scheme 3). 
Inhibition of cysteine cathepsins S and V by organoselenanes
In order to evaluate the relative potency of the 
organoselenanes 1-6 as possible inhibitors of cysteine 
proteases, we selected the cysteine cathepsin S and V 
and a fluorimetric assay to follow the enzymatic activity 
(Figure 2). The reaction progress was monitored 
continuously by the fluorescence of the released product 
(7-amino-4-methylcoumarin, AMC).17,18 
Scheme 2. Reagents and conditions. (i) NaNO2, H2SO4, H2O (0-5 oC); 
(ii) NaHCO3 (pH 7); (iii) THF (0 oC, 1 h); (iv) NaBH4, MeOH (rt, 1 h).
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Scheme 3. Reagents and conditions. (i) vinyl acetate, CAL-B, hexane (32 oC, 24 h); (ii) K2CO3, MeOH, H2O (rt, overnight); (iii) a: NaH (0 oC, 30 min); 
b: MeI, THF (rt, 2 h); (iv) SOCl2 or Br2, THF (0 oC, 15 min).
Figure 2. Fluorimetric enzyme assay for new inhibitors of cysteine cathepsin. (7-amino-4-methylcoumarin).
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Fluorimetric enzyme assays were used to evaluate the 
organoselenanes 1-6 (at 1 µmol L-1) as cysteine cathepsins 
inhibitors (S and V). Initially, the enzyme activities 
were determined by the hydrolysis of the fluorogenic 
substrate Cbz-FR-AMC (1 µmol L-1) in the absence of 
selenanes (Control assay). Then, each organoselenane 1-6 
(1 µmol L-1) was pre-incubated with active cathepsin S 
(Figure 3) and cathepsin V (Figure 4) for 2 min prior to 
the addition of the substrate Cbz-FR-AMC. The residual 
enzyme activities in the presence of each organoselenane 
were determined and the percentage of inhibition was 
determined by direct comparison with the control assay.
In the assays with the cathepsin S, no significant 
differences on the percentage of inhibition for dibromo and 
dichloro organoselenanes was observed. All compounds 
1-6 inhibited about 70-80% of the cathepsin S enzymatic 
activity, demonstrating that for this enzyme steric factors 
or different leaving group attached to the selenium atom 
did not lead to selective interactions. Therefore, the 
low selectivity showed by this enzyme indicates that all 
selenanes 1-6 can be equally used as inhibitor without 
remarkable differentiation. In addition, the possibility 
of the organoselenides intermediates 9, 11, 12 and 14 
being applied as inhibitor of cathepsins S and V was also 
evaluated. As expected, none of these organoselenides 
caused any inhibition at the concentration of 1 µmol L-1 
(For all data, see the Supplementary Information, SI).
On the other hand, assays with the cathepsin V showed 
that the percentages of inhibition observed for dibromo 
derivatives 2, 5 and 6 were higher than the inhibition observed 
for dichloro analogues 1, 3 and 4 (Figure 4). The achiral 
dibromo organoselenane 2 inhibited 95% of the activity 
of this enzyme and the chiral dibromo organoselenanes 5 
and 6 showed 80% of inhibition. From these results, it was 
possible to see that the methyl group attached to the benzyl 
carbon provides a decrease of almost 20% in the percentage 
of inhibition of cathepsin  V by the chiral organoselenanes 
5 and 6 when compared with the organoselenane 2, which 
has no methyl group at that position. However, a discrete 
difference in the inhibition for the organoselenanes 5 and 6 
showed that the stereochemistry of the benzyl carbon was 
not relevant and, consequently no enantiomeric preference 
was observed. Meanwhile, the dichloro organoselenanes 
1, 3 and 4 inhibited about 60% of cathepsin V activity. 
Surprisingly, the structural differences of 1, 3 and 4 did not 
show any significant influence on the inhibition of cathepsin 
V, as observed for the dibromo compounds. In this case it was 
possible to notice that cathepsin V was preferably inhibited 
by dibromo organoselenanes including the influence of 
chirality. It is also important to highlight that this qualitative 
assay showed almost the same inhibitory profile of selenanes 
1-6 against cathepsins V and S. However, kinetic constants of 
the inhibition reaction for each selenane were determined to 
get a detailed study about inhibitors potency and selectivity.
Inhibition kinetics of cathepsins S and V
The second-order rate constants for inactivation 
of cathepsins S and V by organoselenanes 1-6 were 
determined17,18 as illustrated in Figure 5 to cathepsin V 
and organoselenane 2. Initially, it was determined the 
pseudo-first order rate constants (k
obs) for inactivation 
of cathepsin V by different concentrations of selenane 2 
(Figure 5A). Finally, the second-order rate constants (k2) 
were determined by the linear correlation between each 
Figure 3. Inhibition profile for cathepsin S using selenanes 1-6 
(1 µmol L-1). Conditions: Cathepsin S in sodium phosphate buffer 
(50 mmol L-1; pH 6.5) containing EDTA (2.5 mmol L-1). aAverage of 
three determinations.
Figure 4. Inhibition profile for cathepsin V using selenanes 1-6 
(1 µmol L-1). Conditions: Cathepsin V in sodium acetate buffer 
(50 mmol L-1; pH 5.5) containing EDTA (2.5 mmol L-1). aAverage of 
three determinations.
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k
obs and its respective inhibitor concentration, (Figure 5B). 
The second-order inhibitory constant is obtained from the 
slope of the curve k
obs versus inhibitor concentration. This 
method was applied to all compounds against cathepsins V 
and S (see SI and Table 1). 
Organoselenanes showed both time-dependent and 
concentration-dependent behavior on the inhibition of 
cathepsins S and V, as observed in Figure 5A. Dibromo 
organoselenanes (2, 5 and 6) were found to inhibit both 
enzymes more rapidly (Table 1, entries 2, 5 and 6) than 
dichloro analogues (1, 3 and 4; Table 1, entries 1, 3 and 
4). These experimental results can be explained by 
the nucleophilic substitution of a halogen atom of 
organoselenanes by the thiol group of cysteine cathepsin, 
so the best leaving group attached at the selenium atom the 
highest inhibitory potency was observed. Then, dibromo 
organoselenanes 2, 5 and 6 are much more potent than 
chlorine organoselenanes 1, 3 and 4.
The presence of the methyl group at the benzylic carbon 
in the dichloro organoselenanes 3 and 4 (Table 1, entries 3 
and 4) showed a 2-fold improvement in the second-order 
inactivation rate constant of the inhibition of cathepsin V 
when compared to the achiral analogue 1 (Table1, entry 1), 
however, for cathepsin S no difference was observed among 
these compounds. Notably, a distinct pattern was observed 
for dibromo organoselenanes (Table 1, entries 2, 5 and 6) in 
which the presence of methyl group decreased the inhibition 
rate of cathepsin V. Then, the inhibition of cathepsin S by 
the organoselenane 5 (Table 1, entry 5) was 5-fold faster 
than its enantiomer 6 (Table 1, entry 6).
Gel permeation chromatography assays18,19 with 
cathepsin V were used to discriminate between reversible 
and irreversible mechanism for inhibition of cathepsins 
by organoselenanes.18,20 Firstly, cathepsin V was passed 
Figure 5. Time course of the inactivation of cathepsin V with organoselenane 2. (A) The kinetics of inactivation of cathepsin V was performed in sodium 
acetate buffer (50 mmol L-1; pH 5.5) containing EDTA (2.5 mmol L-1), and different concentration of 2: control, 0.5, 1.0, 1.5, 3.0 and 5.0 µmol L-1 of 2. The 
reaction progress was monitored continuously by the fluorescence of the released product (methylcoumarin). (B) Cathepsin V first-order rate inactivation 
in function of organoselenane concentration.
Table 1. Second-order rate constants of the inhibition of cathepsins V 
and S by organoselenanes 
entry Selenane
k2 /(mol L-1s-1)
Cathepsin V Cathepsin S
1
OMe
Se
Cl Cl
1
500 ± 100 1500 ± 400
2
OMe
Se
Br Br
2
3400 ± 200 4000 ± 200
3
OMe
Se
Cl Cl
3
1000 ± 200 1500 ± 380
4
OMe
Se
Cl Cl
4
900 ± 200 1200 ± 300
5
OMe
Se
Br Br
5
2900 ± 560 4900 ± 200
6
OMe
Se
Br Br
6
2200 ± 240 1000 ± 430
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through the gel permeation chromatography column and 
around 18 fractions were collected. The enzyme activity 
was monitored by adding the substrate, Cbz-FR-AMC, to 
each fraction, which indicated the presence of cathepsin V 
in the fractions 6-13 (Figure 6, ()). Secondly, cathepsin V 
was incubated with the most active organoselenane 2 
followed by submitting the mixture to a gel permeation 
chromatography, which resulted around 18 fractions. Each 
fraction was evaluated for cathepsin V activity, however, 
as observed in the Figure 6 none of the fraction collected 
from the column showed enzyme activity (Figure 6, ()). 
The protein content for each fraction was verified by 
measuring the absorption (Figure 6, (---)). In order to 
show the presence of inactive cathepsin V in the fractions 
with protein content (fractions 8-11), the enzyme activity 
was recovered by the addition of 5 mmol L-1 of the 
reducing agent dithiothreitol (DTT), which reduces the 
sulfur-selenium bond in the inactive enzyme, restoring its 
functionality (data not shown).
The inhibition of cathepsins by organoselenanes can 
be based on the reactivity of the selenium(IV) moiety 
toward the thiol group of these enzymes. A nucleophylic 
substitution reaction of the sulfur from cysteine cathepsin 
to the selenium species led to the formation of an S−Se 
covalent bond, which affords the selenium-cathepsin 
adduct, resulting in the irreversible inhibition of these 
enzymes (Figure 7). 
77Se NMR analysis: evidence of the formation of 
organoselenane/thiol adduct
Finally, after the kinetic measurements of the cysteine 
cathepsins inhibition, another evidence of the interaction 
of organoselenanes with thiols was accessed by 77Se 
NMR analysis using cysteine (L-Cys) as a model thiol 
compound (Figure 8). In a NMR tube, the organoselenane 1 
was incubated with increasing ratios of L-Cys (0, 1 and 
2 equiv.) in DMSO-d6. The 77Se NMR spectra of the 
reaction were taken after 1 h of the addition of 1 equiv. of 
cysteine (Figure 8A) and 1 h after the addition of the second 
equivalent (Figure 8B).
By adding the first equivalent of the cysteine, the 
original chemical shift of 1 (549 ppm) disappeared and 
a single new signal at 406 ppm was observed. Two hours 
after the addition of the second equivalent of cysteine, only 
the same signal at 406 ppm was observed. These results 
indicated that the selenium specie that was observed by 
adding one or two equivalents of cysteine was the same. 
Therefore, it suggests that there is a substitution of only 
one atom of chlorine from organoselenane 1 by cysteine 
nucleophilic attack on the selenium atom, indicating that 
the reaction stoichiometry is 1:1. The exchange of one 
chlorine atom at selenium moiety by one sulfur atom 
lead to an increase in the electronic density around the 
selenium atom due to the difference in the electronegativity 
of the ligands, thus a decrease in the 77Se chemical shift is 
observed (549 ppm to 406 ppm). 
Experimental
Unless otherwise noted, commercially available 
materials were used without further purification. Lipase 
from Candida antarctica (fraction B, CAL-B) immobilized, 
Figure 6. Gel permeation of cathepsin V with and without selenane 2. 
Cathepsin V (432 nmol L-1) was incubated with () and without () 
selenane 2 (60 µmol L-1) for 10 min at 27 oC. 500 µL fractions were 
collected and the cathepsin V activity for hydrolysis of Cbz-FR-MCA 
(10 µmol L-1) were determined. The protein content was determined by 
measuring the absorption at A280 of each fraction (dotted line).
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spectra were obtained on a Bruker DRX 300 spectrometer, 
using the appropriate decoupling accessories. All 77Se 
chemical shifts were referenced to internal standard 
PhSeSePh (463 ppm).
Infrared spectra were recorded from KBr discs or from a 
thin film between NaCl plates on FTIR spectrometer (Bomem 
Michelson model 101) with internal reference. Absorption 
maxima (ν
max
) are reported in wavenumbers (cm-1).
High-resolution mass spectra (HRMS) were acquired 
using a Bruker Daltonics MicroTOF instrument, operating 
electrospray ionization (ESI) mode.
Optical rotations were measured on a Perkin Elmer-343 
digital polarimeter in a 1 mL cuvette with a 1 dm 
pathlength. All values are reported in the following format: 
[α]D(temperature of measurement) = specific rotation 
(concentration of the solution reported in units of 10 mg 
sample per 1 mL solvent used).
High performance liquid chromatograph (HPLC) 
analyses for measurement of enantiomeric excesses were 
performed on a Shimadzu, LC-10AD liquid chromatograph 
equipped with an autosampler and a variable wavelength 
UV detector (deuterium lamp 190-600 nm). Chiral 
columns: Chiralcel® OJ-H (0.46 cmf × 25 cm) from Daicel 
Chemical Ind. i-PrOH and hexane (60% n-hexane) HPLC 
grade purchased from J. T. Baker were used as the eluting 
solvents.
Figure 8. 77Se NMR analysis of organoselenane 1. (A) No addition of cysteine; (B) addition of cysteine 1 equiv. (1 h); (C) addition of cysteine 2 equiv. 
(1 h). (d = 463 ppm: internal standard PhSeSePh).
and commercially available as Novozym® 435 was kindly 
donated by Novozymes Latin America Ltda. All solvents 
were HPLC or ACS grade. Solvents used for moisture 
sensitive operations were distilled from drying reagents 
under a nitrogen atmosphere: THF was distilled from Na/
benzophenone. 
Analytical thin-layer chromatography (TLC) was 
performed by using aluminum-backed silica plates coated 
with a 0.25 mm thickness of silica gel 60 F254 (Merck), 
visualized with an ultraviolet light (λ = 254 nm), followed by 
exposure to p-anisaldehyde solution, or vanillin solution and 
heating.
Standard chromatographic purification methods were 
followed using 35-70 mm (240-400 mesh) silica gel 
purchased from Acros Organics®.
Nuclear magnetic resonance (NMR) spectra were 
recorded on a Bruker AC 200 or Bruker DRX 300 
spectrometer at operating frequencies of 200 and 
300 MHz (1H NMR) or 50 and 125 MHz (13C NMR). 
The 1H NMR chemical shifts are reported in ppm 
relative to TMS peak. The data are reported as follows: 
chemical shift (d), multiplicity (s = singlet, d = doublet, 
t = triplet, qd = quadruplet, qt = quintet, st = sextuplet, 
m = multiplet), and coupling constant (J) in Hertz and 
integrated intensity. The 13C NMR chemical shifts are 
reported in ppm relative to CDCl3 signal. The 77Se NMR 
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General procedure for O-methylation reactions (8 and 14)
To a two-necked round-bottomed flask (25 mL) 
containing the appropriate alcohol [7, (S)-12 or (R)-12] 
(1 mmol) in dry THF (10 mL), sodium hydride (48 mg; 2 
mmol) was added. This mixture was stirred at 0 oC (30 min), 
then iodomethane (280 mg; 2 mmol) was added. The 
mixture was stirred for 2 h at room temperature. After that, 
ammonium chloride satured solution (10 mL) was added and 
the organic phase diluted with ethyl acetate (20 mL). The 
organic phase was washed with brine (3 × 10 mL), separated 
and dried over anhydrous magnesium sulphate and filtered. 
The solvent was removed under reduced pressure, and the 
residue was purified by flash chromatography using a mixture 
of n-hexane and ethyl acetate (9:1) as eluent to afford the 
ethers 8, (S)-14 and (R)-14. 
1-Bromo-2-(methoxymethyl)benzene (8): Isolated yield: 
90%; 1H NMR (200 MHz, CDCl3) d: 7.50 (2H, dd, JA 
7.90 Hz; JB 7.46 Hz); 7.31 (1H, m); 7.15 (1H, t, J 7.02 Hz); 
4.53 (2H, s); 3.47 (3H, s); 13C NMR (50 MHz, CDCl3) d: 
137.7; 132.6; 129.1; 129.0; 127.6; 122.9; 74.1; 58.8. 
IR (film) ν
max
/cm-1: 3031; 2986; 2926; 2890; 2822; 1466; 
1443; 1380; 1106; 1207; 749.
Butyl(2-(1-methoxyethyl)phenyl)selane (14): (S)-14: 
Isolated yield: 86%; Enantiomeric excess = 99%; 
[α]D22 = −70.8 (c = 1.06; CHCl3); (R)-14: Isolated yield: 
89%; Enantiomeric excess = 99%; [α]D22 = +70.5 (c = 1.00; 
CHCl3); 1H NMR (200 MHz, CDCl3) d: 7.37 (2H, d, J 7.46 
Hz); 7.55 (2H, m); 4.98 (1H, qd, J 6.4 Hz); 4,20 (2H, qt, J 
7.4 Hz); 3,36 (3H, s), 2,32 (st, 2H, J 7.6 Hz); 1,65 (5H, m); 
1,09 (3H, t, J 7.5 Hz); 13C NMR (50 MHz, CDCl3) d: 145.0; 
132.5; 130.2; 127.9; 127.4; 126.0; 78.2; 56.7; 32.2; 29.9; 
28.0; 23.2; 13.7; 77Se NMR (57.24 MHz, CDCl3) d: 229.8; 
IR (film) ν
max
/cm-1: 3054; 2973; 2959; 2929; 1589; 1572; 
1457; 1214; 1116; 1102; 787; 701. HRMS (ESI), [M+Na]+: 
calculated for C13H20NaOSe = 295.0577. Found 295.0579.
Procedure for the Br/Li exchange reaction 
This procedure was done in an oven-dried two-necked 
round-bottomed flask (25 mL) containing the 2’-bromo-
benzylic ether 8 (187 mg; 1 mmol) in dry THF (10 mL), 
cooled to −78 oC by using dry-ice/acetone bath, tert-
butylitium (0.8 mL of a solution 1.4 mol L-1; 1.1 mmol) was 
added dropwise. Afterwards, the mixture was stirred at 0 oC 
for 30 min and dibutyldiselenide (301 mg; 1.1 mmol) was 
added, and the mixture was stirred for 2 h at room temperature. 
The reaction was quenched by adding ammonium chloride 
satured solution (10 mL), and the organic phase was diluted 
with ethyl acetate (20 mL). The organic phase was washed 
with brine (3 × 10 mL), separated and dried over anhydrous 
magnesium sulphate and filtered. The solvent was removed 
under reduced pressure and the residue was purified by flash 
chromatography, using a mixture of n-hexane and ethyl 
acetate (9:1) as eluent to afford 9 in 90% yield.
Butyl(2-(methoxymethyl)phenyl)selane (9): 1H NMR 
(200 MHz, CDCl3) d: 7.49 (1H, m); 7.22 (1H, m); 7.19 
(2H,m); 4.55 (2H, s); 3.41 (3H, s); 2.89 (2H, t, J 7,0 Hz); 
1.71 (2H, qt, J 6 Hz); 1.58 (2H, st, J 7.45 Hz); 0.90 (3H, 
t, J 7.02 Hz).13C NMR (75 MHz, CDCl3) d: 141.6; 136.6; 
128.4; 127.9; 126.9; 116.6; 78.0; 57.5; 33.6; 25.1; 13.3; 
7.49; 77Se NMR (57.24 MHz, CDCl3) d: 240.0; IR (film) 
ν
max
/cm-1: 3058; 2958; 2928; 2871; 2819; 1436; 1195; 1100; 
748; HRMS (ESI), [M+Na]+: calculated for C12H18NaOSe 
= 281.0421; Found 281.0413.
General procedure for the oxidation of selenides (1-6)21
To an one-necked round-bottomed flask (25 mL) the 
appropriate selenide [8, (S)-14 or (R)-14] (1 mmol) was 
solubilized in dry THF (5 mL). The mixture was cooled 
at 0 oC and then, a cooled solution of sulfuryl chloride 
(1 mmol) or bromine (1 mmol) dissolved in THF (2 mL), 
was added dropwise. The resulting mixture was stirred at 
0 oC for 20 min and then the solvent was removed under 
reduced pressure. The organoselenanes 1-6 were purified 
by recristallization from a mixture of diethyl ether and 
hexane in quantitative yields.
1-[Butyl(dichloro)-λ4-selanyl]-2-(methoxymethyl)
benzene (1): 1H NMR (200 MHz, CDCl3) d: 7.82 (1H, dd, 
JA 3.6 Hz, JB 2.1 Hz ); 7.50 (2H, ddd, JA 3.9 Hz, JB 3.3 Hz, 
JC 2.4 Hz); 7,4 (1H, m); 4.92 (2H, s); 4.14 (2H, t, J 8.1 Hz); 
3.48 (3H, s); 2.29 (2H, qt, J 7.5 Hz); 1.66 (2H, st, J 7.5 
Hz);1.08 (3H, t, J 7.2 Hz). 13C NMR (50 MHz, CDCl3) d: 
141.5; 137.4; 131.4; 128.8; 126.9; 126.5; 73.7; 60.9; 58.7; 
25.8; 22.6. 77Se NMR (57.24 MHz, CDCl3) d: 549.4; IR 
(KBr) ν
max
/cm-1: 3437; 2956; 2927; 2813; 1461; 1445; 
1212; 1199; 1106; 1096. Elemental analysis: Calculated 
for C12H18Cl2OSe: C 49.92; H 5.53; Cl 21.61%. Found: 
C 49.01; H 5.23; Cl 21.43%.
1-[Dibromo(butyl)-λ4-selanyl]-2-(methoxymethyl)
benzene (2): 1H NMR (300 MHz, CDCl3) d: 7.78 (1H, m); 
7.50 (2H m); 7.38 (1H, m); 4.87 (2H, s); 4.08 (2H, t, J 8.1 
Hz); 3.49 (3H, s); 2.26 (2H, qt, J 6 Hz); 1.66 (2H, st, J 7.5 
Hz); 1.09 (3H, t, J 7.2 Hz). 13C NMR (75 MHz, CDCl3) d: 
138.3; 137.7; 131.5; 130.0; 129.9; 129.3; 127.7; 73.8; 
58.8; 25.8; 22.7; 16.7. 77Se NMR (57.24 MHz, CDCl3) d: 
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483.6; IR (KBr) ν
max
/cm-1: 3437; 2992; 2959; 2924; 2822; 
1454; 1442; 1080; 749. Elemental analysis: Calculated 
for C12H18Br2OSe: C 34.56; H 4.35; Br 38.32%. Found: C 
34.36; H 4.37;Br 34.49%.
1-[Butyl(dichloro)-λ4-selanyl]-2-[1-methoxyethyl]
benzene (3 and 4): (S)-3: Isolated yield: 99%; Enantiomeric 
excess = > 99%; [α]D22 = −66.0 (c = 1.02; CHCl3); (R)-4: 
Isolated yield: 99%; Enantiomeric excess = > 99%; 
[α]D22 = +66.2 (c = 1.10; CHCl3); 1H NMR (200 MHz, 
CDCl3) d: 7.74 (1H, d, J 7.9 Hz); 7.55 (3H, m); 4.98 (1H, 
qd, J 6.4 Hz); 4.20 (2H, qt, J 7.4 Hz); 3.36 (3H, s), 2.32 (st, 
2H, J 7.6 Hz); 1.65 (5H, m); 1.09 (3H, t, J 7.5 Hz); 13C NMR 
(50 MHz, CDCl3) d: 142.6; 141.2; 132.3; 129.5; 128.2; 
125.6; 76.9; 62.4; 57.2; 26.0; 22.7 (2C); 13.8.77Se NMR 
(57.24 MHz, CDCl3) d: 508.1; IR (KBr)) νmax/cm-1: 
3447; 2984; 2973; 2961; 2866; 1465; 1442; 1370; 1208; 
1110; 1052; 756. Elemental analysis: Calculated for 
C13H20Cl2OSe: C 45.63; H 5.89; Cl 20.72%. Found: C 
45.53; H 5.83; Cl, 20.73%.
1-[Dibromo(butyl)-λ4-selanyl]-2-[1-methoxyethyl)
benzene (5 and 6): (S)-5: Isolated yield: 99%; Enantiomeric 
excess = > 99%; [α]D22 = −80.0 (c = 1.00; CHCl3); (R)-6: 
Isolated yield: 99%; Enantiomeric excess = > 99%; 
[α]D22 = +79.8 (c = 1.00; CHCl3); 1H NMR (200 MHz, 
CDCl3) d: 7.88 (1H, d, J 7,9 Hz); 7.49 (2H, m); 7.36 (1H, 
m); 4.98 (1H, qd, J 6.58 Hz); 3.71 (2H, qt, J 7.02 Hz); 
3.54 (3H, s); 2.22 (2H, qt, J 7.46 Hz); 1.62 (5H, m); 1.07 
(3H, t, J 7.5 Hz).13C NMR (50 MHz, CDCl3) d: 143.5; 
131.8; 131.5; 129.8; 129.2; 127.8; 78.7; 56.5; 45.9; 26.8; 
24.7; 20.1; 13.8. IR (KBr) ν
max
/cm-1: 3442; 2976; 2957; 
2928; 2870; 2824; 1462; 1441; 1105. Elemental analysis: 
Calculated for C13H20Br2OSe: C 36.22; H 4.68; Br 37.07%. 
Found: C 36.3; H 4.65; Br 36.97%.
General procedure for the arenediazonium salt reaction 
with lithium organoselenolate
The 2’-amino-acetophenone 10 (405 mg; 3 mmol), 
sulfuric acid (0.8 mL) and water (0.8 mL) were mixed 
in a 25 mL round-bottomed flask. The solution was 
cooled to 0 oC and an aqueous solution of sodium nitrite 
(276 mg, 4 mmol in 1 mL of water) was added dropwise 
with vigorous stirring. The mixture was stirred for 5 min 
and aqueous solution of sodium bicarbonate was added 
slowly until pH 7. This solution was then transferred 
to another 50 mL flask containing a solution of lithium 
butylselenolate (1 mmol) in THF (3 mL). The biphasic 
solution was continuously stirred at room temperature 
until the gas evolution had ceased. Afterwards, the mixture 
was diluted with brine (20 mL) and extracted with ethyl 
acetate (2 × 20 mL). The organic phase was separated and 
dried over anhydrous magnesium sulphate and filtered. 
The solvent was removed under reduced pressure and 
the residue was purified by flash chromatography using 
a mixture of n-hexane and ethyl acetate (9:1) as eluent to 
afford 11 in 45% yield.
1-(2-(Butylselanyl)phenyl)ethanone (11): Isolated 
yield: 45%; 1H NMR (200 MHz, CDCl3) d: 7.90 (d, 1H, 
J 7.9 Hz); 7.44 (m, 2H); 7.23 (m, 1H); 2.84 (t, 2H, J 7.5 
Hz); 2.63 (s, 3H); 1.72 (qt, 2H, J 6.9 Hz), 1.50 (st, 3 H, 
J 7.3 Hz); 0.95 (t, 3H, J 7.2 Hz); 13C NMR (50 MHz, 
CDCl3) d: 98.9; 138.5; 135.5; 132.4; 131.8; 128.4; 124.3; 
30.8; 27.7; 24.8; 23.5; 13.8; IR (film) ν
max
/cm-1: 2957
, 
2928, 
1666,1457, 1428, 1248; HRMS (ESI), [M+Na]+: calculated 
for C12H16OSeNa = 279.0264. Found 279.0260.
Enzymatic kinetic resolution of 1-(2-(butylselanyl)phenyl)
ethanol (12)
To an one-necked round-bottomed flask (100 mL) 
containing 1-(2-(butylselanyl)phenyl)ethanol rac-12 
(1.285 g; 5 mmol) in hexane (20 mL), CAL-B (Novozyme 
435; 400 mg) and vinyl acetate (0.86 g; 15 mmol) were 
added. The mixture was stirred in an orbital shaker at 32 oC 
for 24 h (160 rpm). Following that, the enzyme was filtered 
off and washed with dichloromethane (3 × 20 mL). The 
solvent was removed under reduced pressure and the residue 
was purified by flash chromatography using a mixture of 
n-hexane and ethyl acetate (9:1) as eluent to afford (S)-12 
(ee 99%) and (R)-13 (ee 99%) in 45% yield each one.
 (S)-1-(2-(butylselanyl)phenyl)ethanol (12): Isolated 
yield = 45%; Enantiomeric excess > 99%; [α]D22 = −23,9 
(c = 0.78; CHCl3); 1H NMR (200 MHz, CDCl3) d: 7.50 (m, 
2H); 7.23 (m, 2H); 5.30 (qd, 1H, J 6.3 Hz); 2.91 (t, 2H, J 
7.5 Hz); 2,3 (s, 1H); 1.70 (qt, 2H, J 7.4 Hz); 1.44 (m, 5H); 
0.96 (t, 3H, J 7.24); 13C NMR (50 MHz, CDCl3) d: 146.9; 
132.7; 129.4; 128.0; 127.4; 125.6; 69.3; 32.2; 28.2; 24.3; 
23.2; 13.7; IR (film) ν
max
/cm-1: 3361, 3057, 2961, 2928, 
2870, 1463, 1008, 754; HRMS (ESI), [M+Na]+:calculated 
for C12H18OSeNa = 281.0421. Found 281.0416.
(R)-1-(2-(butylselanyl)phenyl)ethyl acetate (13): 
Isolated yield = 45%; Enantiomeric excess > 99%; 
[α]D22 = +36.1 (c = 0.80; CHCl3); 1H NMR (200 MHz, 
CDCl3) d: 7.51 (1H, dd, J 1.30 Hz); 7.41 (1H, dd, J 1.70 
Hz); 7,22 (m, 2H); 6.29 (qd, 1H, J 6.58 Hz); 2.91 (t, 2H, J 
7.5 Hz); 2.92 (2H, t, J 7.5 Hz); 2.08 (1H, s); 1.70 (2H, qt, 
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J 7.90 Hz); 1.44 (m, 5H); 0.92 (3H, t, J 7.02); 13C NMR 
(50 MHz, CDCl3) d:170.2; 143.9; 136.7; 133.8; 128.3; 
127.6; 125.8; 72.1; 32.2; 28.4; 23.1; 22.0; 21.4; 13.7. IR 
(film) ν
max
/cm-1: 3058; 2959; 2930; 2870; 1735; 1466; 1370; 
1237; 1070, 757 cm-1; HRMS (ESI), [M+Na]+: calculated 
for C14H20OSeNa = 323.0526. Found 323.0515.
Screening for inhibitory activity of organoselenanes against 
cathepsins S and V 
The cathepsins kinetics of Cbz-FR-MCA hydrolysis 
were performed in the optimal conditions for each enzyme. 
Cathepsin S (1.5 nmol L-1): sodium phosphate buffer 
(50 mmol L-1; pH 6.5) containing EDTA (2.5 mmol L-1); 
Cathepsin V (3.2 nmol L-1): sodium acetate buffer 
(50 mmol L-1; pH 5.5) containing EDTA (2.5 mmol L-1). The 
screening of the inhibition of cathepsins was performed by 
the incubation of each cathepsin with the organoselenanes 
1-6 (1 µmol L-1) for 2 min in the appropriate buffer solution 
at 37 oC, then the fluorogenic substrate Cbz-FR-ACM was 
added and the remaining enzyme activity was determined. 
The residual cathepsin activities (A2) were expressed as a 
percentage of the activity of from the control experiment 
(A1; in the absence of selenanes) by the following ratio: 
Residual Enzymatic Activity (%) = (A2/A1) × 100
Inactivation kinetics
Cathepsins activities were monitored spectro-
fluorometrically using the fluorogenic substrate 
Cbz-FR-AMC on a Hitachi F-2000 spectrofluorometer 
equipped with a thermostated cell holder. The excitation 
and emission wavelengths were set at 380 and 460 nm, 
respectively. The continuous method16 was employed and 
the inhibition of activated cysteine proteases were carried 
out in the presence of substrate and different concentrations 
of each organoselenane, as described before.17 The substrate 
concentrations were kept 10-fold below the KM values. The 
kinetics of cathepsin inactivation by organoselenanes were 
obtained in pseudo-first-order conditions. The inhibition 
reaction was monitored continuously by the fluorescence 
of the enzymatic-released Cbz-FR-AMC. The hydrolysis 
progress curves were obtained in pseudo-first-order 
conditions and treated by non-linear regression according 
to equation 1 as reported previously:22 
P = (v
z
 /k
obs) [1−exp (−kobs t)]+d (1)
where P is the product concentration (in our case it is 
proportional to the fluorescence of AMC) at a given time, 
v
z
 is velocity of substrate hydrolysis for zero time and k
obs 
is the observed first-order rate of organoselenane-induced 
enzyme inactivation and d is the basal fluorescence before 
adding the enzyme.
Determination of inhibition mechanism by gel permeation 
chromatography
In order to show the irreversible inhibition of 
cathepsins by organoselenanes, the most potent inhibitor, 
organoselenane 2, was chosen and used as follows.
Gel permeation chromatography of cathepsin V: A 
2.5 mL solution of activated cathepsin V was loaded 
on a 1×10-cm Sephadex G-25 column (Amersham PD-
10 column, Amersham), pre-equilibrated with sodium 
acetate buffer (50 mmol L-1, pH 5.5) containing EDTA 
(2.5 mmol L-1) at 27 oC. Around 18 fractions (500 µL 
fractions) were collected. The enzyme activity was 
monitored by adding the substrate, Cbz-FR-AMC, to each 
fraction.
Gel permeation chromatography of cathepsin V and 
organoselenane 2: A solution of activated cathepsin V 
was incubated with the most active organoselenane 2 
(10 mmol L-1), in a total volume of 2.5 mL, for 10 min. 
Then, this mixture was loaded on a 1×10-cm Sephadex 
G-25 column (Amersham PD-10 column, Amersham), 
pre-equilibrated with sodium acetate buffer (50 mmol L-1, 
pH 5.5) containing EDTA (2.5 mmol L-1) at 27 oC. Around 
18 fractions (500 µL fractions) were collected. The 
enzyme activity was monitored by adding the substrate, 
Cbz-FR-AMC, to each fraction. The protein content for 
each fraction was verified by measuring the absorption 
A280.
Conclusions
We have synthesized a series of hypervalent 
organoselenium compounds (organoselenanes), and 
it has been demonstrated, for the first time, that these 
compounds can be efficiently used as cysteine protease 
inhibitors. The inhibition of these enzymes is irreversible 
and showed a time-dependent and concentration-
dependent behavior. In addition, the enzyme activity 
was totally restored after the treatment of the selenium-
cathepsin adduct (inactive enzyme) with the reducing 
agent dithiothreitol (DTT). We expect that the present 
report will provide a good basis for the development of 
novel cysteine protease inhibitors based on selenium(IV) 
compounds. 
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Supplementary Information
Supplementary information, with characterization data 
(1H, 13C and 77Se NMR, IR and mass spectrometry) for all 
compounds and enantiomeric separation for chiral selenium 
compounds by chiral HPLC, are available, free of charge, 
at http://jbcs.sbq.org.br, as PDF file.
Acknowledgments
We thank CNPq, CAPES and FAPESP for financial 
support.
References
 1. Nogueira, C. W.; Zeni, G.; Rocha, J. B.T.; Chem. Rev. 2004, 
104, 6255; Mugesh, G.; du Mont, W-W.; Sies, H.; Chem. Rev. 
2001, 101, 2125.
 2. Schwarz, K.; Foltz, C. M.; J. Am. Chem. Soc. 1957, 79, 3292.
 3. Rotruck, J. T.; Ganther, H. E.; Swanson, A. B.; Hafeman, D. G.; 
Hoekstra, W. G.; Science 1973, 179, 588; Mai, J.; Sorensen, P. 
S.; Hansen, J. C.; Biol. Trace Elem. Res. 1990, 24, 109.
 4. Battin, E. E.; Brumaghim, J. L.; Cell Biochem. Biophys. 2009, 
55, 1; Bhabak, K. P.; Mugesh, G.; Chem. Asian J. 2009, 4, 974; 
Schewe, T.; Gen. Pharmacol. 1995, 26, 1153.
 5. Sanmartin, C.; Plano, D.; Palop, J. A.; Mini-Rev. Med. Chem. 
2008, 8, 1020; Duntas, L. H.; Horm. Metab. Res. 2009, 41, 443.; 
Rikiishi, H.; J. Bioenerg. Biomembr. 2007, 39, 91; Fleming, J.; 
Ghose, A.; Harrison, P. R.; Nutr. Cancer 2001, 40, 42.
 6. Combs Jr., J. F.; Gray, W. P.; Pharmacol. Ther. 1998, 79, 179.
 7. El-Bayoumy, K.; Can. Res. 1985, 45, 3631; Schrauzer, G. N.; 
Crit. Rev. Biotechnol. 2009, 29, 10.
 8. Cao, S.; Durrani, F. A.; Rustum, Y. M.; Clinical Cancer Res. 
2004, 10, 2561.
 9. Zhou, N.; Xiao, H.; Li, T-K.; Nur-E-Kamal; A.; Liu, L. F.; 
J. Biol. Chem. 2003, 278, 29532; Sinha, R.; El-Bayoumy, K.; 
Curr. Cancer Drug Targets 2004, 4, 13.
 10. Ganther, H. E.; Carcinogenesis 1999, 20, 1657.
 11. Engman, L.; Tetrahedron Lett. 1985, 26, 638..
 12. Bhabak, K. P.; Mugesh, G.; Inorg. Chem. 2009, 48, 2449.
 13. Abdo, M.; Liu, S.; Zhou, B.; Walls, C. D.; Wu, L.; Knapp, S.; 
Zhang, Z. Y.; J. Am. Chem. Soc. 2008, 130, 13196.
 14. Krief, A.; Dumont, W.; Denis, J.; J. Chem. Soc., Chem. Commun. 
1985, 571; Tiecco, M.; Chianelli, D.; Testaferri, L.; Tingoli, M.; 
Bartoli, D.; Tetrahedron 1986, 42, 4889; Tiecco, M.; Testaferri, 
L.; Bagnolli, L.; Scarponi, C.; Temperini, A.; Marini, F.; Santi, 
C.; Tetrahedron: Asymm. 2007, 18, 2758.
 15. Joyce, J. A.; Gocheva, V.; Cell Cycle 2007, 6, 60; Brömme, D.; 
Kaleta, J.; Curr. Pharm. Design 2002, 8, 1639.
 16. Joyce, J. A.; Palermo, C.; Trends Pharmacol. Sci. 2007, 29, 22.
 17. Brubacher, L. J.; Glick, B. R.; Biochemistry 1979, 13, 915; 
Johnson, L. A.; Moon, K. E.; Eisenberg, M.; Biochim. Biophys. 
Acta 1988, 953, 269.
 18. Cunha, R. L. O. R.; Urano, M. E.; Chagas, J. R.; Almeida, P. 
C.; Bincoletto, C.; Tersariol, I. L. S.; Comasseto, J. V.; Bioorg. 
Med. Chem. Lett. 2005, 15, 755; Persike, D. S.; Cunha, R. L. 
O. R.; Juliano, L.; Silva, I. R. ; Rosim, F. E.; Vignoli, T.; Dona, 
F.; Cavalheiro, E.A.; Fernandes, M. J.; Neurobiol. Dis. 2008, 
31, 120; Cunha, R. L. O. R.; Gouvea, I. E.; Feitosa, G. P. V.; 
Alves, M. F. M.; Brömme, D.; Comasseto, J. V.; Tersariol, I. 
L. S.; Juliano, L.; Biol. Chem. 2009, 390, 2305. 
 19. Silverman, R. B.; Methods Enzymol. 1995, 249, 240.
 20. Silverman, R. B.; Methods Enzymol. 1995, 249, 240.
 21. Procedure adapted from: Engman, L.; Organometallics 1984, 
3, 1308.
 22. Baici, A.; Schenker, P.; Wachter, M.; Ruedi, P.; Chem. 
Biodiversity 2009, 6, 261.
Submitted: March 12, 2010
Published online: July 20, 2010
FAPESP has sponsored the publication of this article.
Supplem
entary Inform
ation
J. Braz. Chem. Soc., Vol. 00, No. 00, S1-S26, 2010.
Printed in Brazil - ©2010  Sociedade Brasileira de Química
0103 - 5053  $6.00+0.00
*e-mail:  rodrigo.cunha@ufabc.edu.br; leandroh@iq.usp.br
Chemoenzymatic Synthesis of Organoselenium(IV) Compounds and their 
Evaluation as Cysteine Protease Inhibitors
Leandro Piovan,a Márcio F. M. Alves,b Luiz Juliano,b Dieter Brömme,c 
Rodrigo L. O. R. Cunha*,b,d and Leandro H. Andrade*,a
aInstituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, 
05508-900 São Paulo-SP, Brazil
bDepartamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, 
Rua Três de Maio 100, 04044-200 São Paulo-SP, Brazil
cDepartment of Dentistry and UBC Center for Blood Research, University of British Columbia, 
Faculty of Dentistry, Vancouver V6T 1Z3, Canada
d Centro de Ciências Naturais e Humanas (CCNH), Universidade Federal do ABC, 
Av. dos Estados 5001, 09210-580 Santo André-SP, Brazil
Figure S1. 1H NMR (200 MHz, CDCl3) spectrum of 1-(2-(butylselanyl)phenyl)ethanone (11).
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Figure S2. 13C NMR (50 MHz, CDCl3) spectrum of 1-(2-(butylselanyl)phenyl)ethanone (11).
Figure S3. Infrared spectrum of 1-(2-(butylselanyl)phenyl)ethanone (11).
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Figure S5. 1H NMR (200 MHz, CDCl3) spectrum of 1-(2-(butylselanyl)phenyl)ethanol (12).
Figure S4. High resolution mass spectrum (ESI) of 1-(2-(butylselanyl)phenyl)ethanone (11).
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Figure S6. 13C NMR (50 MHz, CDCl3) spectrum of 1-(2-(butylselanyl)phenyl)ethanol (12).
Figure S7. Infrared spectrum of 1-(2-(butylselanyl)phenyl)ethanol (12).
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Figure S9. 1H NMR (200 MHz, CDCl3) spectrum of 1-(2-(butylselanyl)phenyl)ethyl acetate (13).
Figure S8. High resolution mass spectrum (ESI) of 1-(2-(butylselanyl)phenyl)ethanol (12).
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Figure S10. 13 C NMR (50 MHz, CDCl3) spectrum of 1-(2-(butylselanyl)phenyl)ethyl acetate (13).
Figure S11. Infrared spectrum of 1-(2-(butylselanyl)phenyl)ethyl acetate (13).
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Figure S12. High resolution mass spectrum (ESI) of 1-(2-(butylselanyl)phenyl)ethyl acetate (13).
Figure S13. 1H NMR (200 MHz, CDCl3) spectrum of butyl(2-(1-methoxyethyl)phenyl)selane (14).
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Figure S14. 13C NMR (50 MHz, CDCl3) spectrum of butyl(2-(1-methoxyethyl)phenyl)selane (14).
Figure S15. 77Se NMR (57.24 MHz, CDCl3) spectrum of butyl(2-(1-methoxyethyl)phenyl)selane (14).
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Figure S16. Infrared spectrum of butyl(2-(1-methoxyethyl)phenyl)selane (14).
Figure S17. High resolution mass spectrum (ESI) of butyl(2-(1-methoxyethyl)phenyl)selane (14).
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Figure S18. 1H NMR (200 MHz, CDCl3) spectrum of selenane (3 or 4).
Figure S19. 13C NMR (50 MHz, CDCl3) spectrum of selenane (3 or 4).
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Figure S21. Infrared spectrum of selenane (3 or 4).
Figure S20. 77Se NMR (57.24 MHz, CDCl3) spectrum of selenane (3 or 4).
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Figure S22. 1H NMR (200 MHz, CDCl3) spectrum of selenane (5 or 6).
Figure S23. 13C NMR (50 MHz, CDCl3) spectrum of selenane (5 or 6).
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Figure S24. 77Se NMR (57.24 MHz, CDCl3) spectrum of selenane (5 or 6).
Figure S25. Infrared spectrum of selenane (5 or 6).
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Figure S26. 1H NMR (200 MHz, CDCl3) spectrum of 1-bromo-2-(methoxymethyl)benzene (8).
Figure S27. 13C NMR (50 MHz, CDCl3) spectrum of 1-bromo-2-(methoxymethyl)benzene (8).
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Figure S28. Infrared spectrum of 1-bromo-2-(methoxymethyl)benzene (8).
Figure S29. 1H NMR (200 MHz, CDCl3) spectrum of butyl(2-(methoxymethyl)phenyl)selane (9).
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Figure S30. 13C NMR (75 MHz, CDCl3) spectrum of butyl(2-(methoxymethyl)phenyl)selane (9).
Figure S31. 77Se NMR (57.24 MHz, CDCl3) spectrum of butyl(2-(methoxymethyl)phenyl)selane (9).
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Figure S32. Infrared spectrum of butyl(2-(methoxymethyl)phenyl)selane (9).
Figure S33. High resolution mass spectrum (ESI) of butyl(2-(methoxymethyl)phenyl)selane (9).
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Figure S34. 1H NMR (200 MHz, CDCl3) spectrum of selenane 1.
Figure S35. 13 C NMR (75 MHz, CDCl3) spectrum of selenane 1.
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Figure S36. 77Se NMR (57.24 MHz, CDCl3) spectrum of selenane 1.
Figure S37. Infrared spectrum of selenane 1.
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Figure S38. 1H NMR (300 MHz, CDCl3) spectrum of selenane 2.
Figure S39. 13C NMR (75 MHz, CDCl3) spectrum of selenane 2.
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Figure S40. 77Se NMR (57.24 MHz, CDCl3) spectrum of selenane 2.
Figure S41. Infrared spectrum of selenane 2.
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Figure S42. Inhibition profile for cathepsin V using selenides 9, 11, 12 
and 14 (1 mmol L-1). Conditions: Cathepsin V in sodium acetate buffer 
(50 mmol.L-1; pH 5.5) containing EDTA (2.5 mmol L-1).a Average of 
three determinations.
Figure S43. Inhibition profile for cathepsin S using selenides 9, 11, 
12 and 14 (1 mmol.L-1). Conditions: Cathepsin V in sodium phosphate 
buffer (50 mmol L-1; pH 6.5) containing EDTA (2.5 mmol L-1). aAverage 
of three determinations.
Figure S44. Enzyme kinetic for cathepsin V using  selenane 1 as inhibitor.
Figure S45. Enzyme kinetic for cathepsin V using  selenane 2 as inhibitor.
Inhibition of cysteine cathepsins V and S by organoselenides 
9, 11, 12 and 14
Enzyme kinetics for cathepsins 
Time course of the hydrolysis of fluorogenic 
substrate (Cbz-FR-AMC) in the presence and absence of 
organoselenanes in the indicated concentrations; relation 
of the observed first-order inactivation constants (k
obs) and 
the used organoselanes concentrations
Piovan et al. S23Vol. 00, No. 00, 2010
Figure S46. Enzyme kinetic for cathepsin V using  selenane 3 as inhibitor.
Figure S47. Enzyme kinetic for cathepsin V using  selenane 4 as inhibitor. Figure S49. Enzyme kinetic for cathepsin V using  selenane 6 as inhibitor.
Figure S48. Enzyme kinetic for cathepsin V using  selenane 5 as inhibitor.
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Figure S50. Enzyme kinetic for cathepsin S using  selenane 1 as inhibitor.
Figure S51. Enzyme kinetic for cathepsin S using selenane 2 as inhibitor.
Figure S52. Enzyme kinetic for cathepsin S using selenane 3 as inhibitor.
Figure S53. Enzyme kinetic for cathepsin S using selenane 4 as inhibitor.
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Figure S54. Enzyme kinetic for cathepsin S using selenane 5 as inhibitor.
Figure S56. Enzymatic kinetic resolution of (RS)-12. The enantioenriched compounds (S)-12 and (R)-12 were prepared according to the method described 
in the text. 
Figure S55. Enzyme kinetic for cathepsin S using selenane 6 as inhibitor.
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Figure S57. (S)-1-(2-(butylselanyl)phenyl)ethanol (12): Isolated yield = 45%; Enantiomeric excess > 99%; [a]D22 = -23.9 (c = 0.78; CHCl3). HPLC 
condition: Chiralcel® OJ-H column, n-hexane/i-PrOH (99:1), 1.0 mL min-1, 254 nm UV detector, tR =  15.8 min.
Figure S58. (R)-1-(2-(butylselanyl)phenyl)ethanol (12): Isolated yield = 45%; Enantiomeric excess > 99%; [a]D22 = + 24.1 (c = 0.80; CHCl3). HPLC 
condition: Chiralcel® OJ-H column, n-hexane/i-PrOH (99:1), 1.0 mL min-1, 254 nm UV detector, tR =  17.3 min.
